Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVI Global Trust Regulatory News (AGT)

Share Price Information for AVI Global Trust (AGT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 245.00
Bid: 244.50
Ask: 245.00
Change: 1.00 (0.41%)
Spread: 0.50 (0.204%)
Open: 242.50
High: 245.50
Low: 242.50
Prev. Close: 244.00
AGT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Update

19 Jul 2022 11:44

RNS Number : 9875S
AVI Global Trust PLC
19 July 2022
 

 

AVI GLOBAL TRUST PLC

 

Monthly Update

 

AVI Global Trust plc (the "Company") presents its Update, reporting performance figures for the month ended 30 June 2022.

 

This Monthly Newsletter is available on the Company's website at:

https://www.assetvalueinvestors.com/agt/content/uploads/2022/07/AGT-June-2022.pdf

 

 

Performance Total Return

 

This investment management report relates to performance figures to 30 June 2022.

 

Month

Fiscal Yr*

to date

Calendar Yr

to date

AGT NAV1

-5.9%

-7.3%

-12.9%

MSCI ACWI Ex US2

-5.2%

-7.8%

-9.0%

MSCI ACWI1

-5.0%

-5.5%

-11.0%

 

1

Source: Morningstar. All NAV figures are cum-fair values.

2

From 1st October 2013 the lead benchmark was changed to the MSCI ACWI ex US (£) Index. The investment management fee was changed to 0.7% of net assets and the performance related fee eliminated.

 

* All return figures in GBP. AVI Global Trust financial year commences on the 1st October. All figures published before the fiscal results announcement are AVI estimates and subject to change.

 

Manager's Comment

 

AVI Global Trust (AGT)'s NAV declined -5.9% in June.

 

Following much higher than anticipated inflation figures, the consensus has now become that central banks will do "whatever it takes" to rid us of inflation - with the "whatever" part including causing a recession. Meanwhile inflation and higher energy prices are squeezing consumer budgets and putting pressure on corporate profit margins. All of this provides an uncomfortable backdrop for equities.

 

Within this context, performance was weak across the board, as NAV declines compounded by a widening of the portfolio weighted average discount from 32.3% to 34.1%. Five holdings - Sony, Wacom, KKR, EXOR and Aker - all detracted 50-115bps from returns, with local share price returns of between -8% and -16%.

 

EXOR

 

EXOR was a meaningful detractor, knocking 81bps off returns. The shares declined -13% as a -6% decline in NAV was compounded by a widening of the discount from 42% to 47%.

 

Starting with the NAV side of the equation, the key culprit was Stellantis (20% of NAV), shares in which declined -15% over the month, bringing year to date returns to -24%. Investors have grown increasingly cautious over the state of the global economy generally, and the US consumer specifically, whilst there is a broader debate in autos as to whether current record high margins and low dealer incentives will stick when volumes (hitherto restricted by shortages of semiconductor chips) return. Stellantis now trades at 3x consensus 2022 earnings - a ~40-60% discount to Ford and GM once adjusting for accounting differences. As one sell side analyst put it in a recent note: "What does the market fear? Clearly the answer is "a lot". With such low expectations there appears ample room for surprise on the upside - much to the benefit of EXOR's NAV.

As we have noted at various points this year, whilst discounts have been widening in the main they haven't yet reached the screamingly cheap levels observed in other market corrections. At a 47% discount EXOR on the other hand is now approaching that stage. The maths of discount returns from extreme levels are powerful: a return to the 35% five-year average takes the shares +23% higher, whilst a re-rating to the low 20s (where EXOR traded, albeit rather briefly, pre-pandemic) yields a return of +50%.

So what events might lead to this happening? In our view, it likely all comes down to the allocation of the ($9bn) Partner Re proceeds. Holding companies must give investors a "reason" to own their shares and as such diversification into attractive quality unlisted assets is an important step in sustainably reducing the discount at which EXOR trades. Shortly after quarter-end it was announced that EXOR will invest €833m (3% of NAV) for a 10% stake in Institut Mérieux, the unlisted healthcare-focused holding company of the Mérieux family. The vast bulk (~80%) of Institut Mérieux's value lies in a 59% listed stake in bioMérieux, the in vitro diagnostics business focused on infectious diseases. We expect EXOR to continue to allocate capital to higher growth, less cyclical and industrial assets such as this, which over time will help shift investor perception and the discount. Combined with the prospects for NAV growth, prospective returns appear attractive.

Fujitec

 

At the end of June we released a public statement questioning whether Fujitec's current outside directors were acting in the best interests of shareholders. Subsequent to the public release of our presentation in May 2020, we have conducted all our dialogue privately, making excellent progress on several issues. However, Fujitec's response to legitimate concerns raised by Oasis Management in May regarding related-party transactions between Fujitec and former President Mr Uchiyama fell a long way short of what we expect from a listed company.

 

Despite the Board's efforts to exonerate Mr Uchiyama of any wrongdoing, we remain entirely unconvinced that the numerous related-party transactions undertaken by Mr Uchiyama and his family do not pose a problem for corporate governance. In recognition of that, we voted against Mr Uchiyama's reappointment at Fujitec's 2022 AGM along with three other outside directors.

 

However, in what we think was an effort to conceal a low approval rating for Mr Uchiyama's reappointment, the motion to reappoint him as President was withdrawn one hour before the AGM. Then, shortly after the AGM, Mr Uchiyama was reappointed as Chairman without the approval of shareholders.

 

We are astounded by the clear disregard for shareholder rights and Fujitec's blatant effort to circumnavigate the AGM voting process. We are not alone - two other shareholders holding almost 16% of the shares released a public statement following the AGM debacle and we know from private conversations that many shareholders share the same views.

 

The Board has lost the support of its shareholders and the current situation cannot continue. As we discussed in our public statement, we are proactively evaluating our next steps to protect shareholder value. What form that might take is still being decided but we won't sit idly by while shareholder rights are being ignored.

 

Trading activity

 

During the period we started to build a new position in a European holding company that is currently trading ~60% below its 52-week high, with attractive quality assets and potential for significant value unlocking corporate events. We are still accumulating shares across our funds but expect to discuss the company in due course.

 

Contributors / Detractors (in GBP)

 

Largest Contributors

1- month contribution

bps

% of NAV

Fondul Proprietatea

47

4.2

Fujitec

21

2.1

Swire Pacific Ltd 'B'

7

2.6

Daiwa Industries

4

0.6

Teikoku Sen-I

2

0.4

 

Largest Detractors

1- month contribution

bps

% of NAV

Aker ASA

-115

6.1

EXOR

-81

6.4

KKR

-69

5.3

Wacom

-56

3.5

Sony Group

-53

5.1

 

 

 

Link Company Matters Limited

Corporate Secretary

 

19 July 2022

 

LEI: 213800QUODCLWWRVI968

 

The content of the Company's web-pages and the content of any website or pages which may be accessed through hyperlinks on the Company's web-pages, other than the content of the Newsletter referred to above, is neither incorporated into nor forms part of the above announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFSIDFIALIF
Date   Source Headline
10th May 20244:43 pmRNSHolding(s) in Company
10th May 20241:35 pmRNSNet Asset Value(s)
9th May 20245:55 pmRNSTransaction in Own Shares
9th May 202412:46 pmRNSNet Asset Value(s)
8th May 20241:27 pmRNSNet Asset Value(s)
7th May 20241:18 pmRNSNet Asset Value(s)
3rd May 20242:08 pmRNSNet Asset Value(s)
2nd May 20245:43 pmRNSTransaction in Own Shares
2nd May 20241:55 pmRNSNet Asset Value(s)
1st May 20241:39 pmRNSNet Asset Value(s)
1st May 20247:00 amRNSTotal Voting Rights
30th Apr 202412:30 pmRNSNet Asset Value(s)
29th Apr 20241:34 pmRNSNet Asset Value(s)
26th Apr 202412:06 pmRNSNet Asset Value(s)
25th Apr 20241:57 pmRNSNet Asset Value(s)
24th Apr 202412:34 pmRNSNet Asset Value(s)
23rd Apr 20241:00 pmRNSNet Asset Value(s)
22nd Apr 202412:54 pmRNSNet Asset Value(s)
19th Apr 20245:35 pmRNSTransaction in Own Shares
19th Apr 20243:39 pmRNSNet Asset Value(s)
19th Apr 20247:00 amRNSCompliance with Market Abuse Regulation
18th Apr 20245:40 pmRNSTransaction in Own Shares
18th Apr 202412:18 pmRNSNet Asset Value(s)
17th Apr 202412:24 pmRNSNet Asset Value(s)
16th Apr 202412:31 pmRNSNet Asset Value(s)
15th Apr 202412:44 pmRNSNet Asset Value(s)
12th Apr 20245:30 pmRNSTransaction in Own Shares
12th Apr 20242:09 pmRNSNet Asset Value(s)
11th Apr 20245:49 pmRNSTransaction in Own Shares
11th Apr 202412:59 pmRNSNet Asset Value(s)
10th Apr 20245:44 pmRNSTransaction in Own Shares
10th Apr 20241:01 pmRNSNet Asset Value(s)
9th Apr 20245:40 pmRNSTransaction in Own Shares
9th Apr 20243:48 pmRNSMonthly Factsheet
9th Apr 202412:20 pmRNSNet Asset Value(s)
9th Apr 202411:56 amRNSDirector/PDMR Shareholding
8th Apr 20244:58 pmRNSDirector/PDMR Shareholding
8th Apr 202412:58 pmRNSNet Asset Value(s)
8th Apr 202412:53 pmRNSAppointment of Corporate Broker
8th Apr 202412:39 pmRNSListing Rule 15.6.8
5th Apr 20241:57 pmRNSNet Asset Value(s)
4th Apr 20245:32 pmRNSTransaction in Own Shares
4th Apr 20241:13 pmRNSNet Asset Value(s)
3rd Apr 20245:32 pmRNSTransaction in Own Shares
3rd Apr 20242:28 pmRNSNet Asset Value(s)
3rd Apr 20247:00 amRNSKepler Trust Intelligence: New Research
2nd Apr 20245:30 pmRNSTransaction in Own Shares
2nd Apr 20244:32 pmRNSNet Asset Value(s)
2nd Apr 202412:31 pmRNSTotal Voting Rights
28th Mar 20245:32 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.